In addition to the in vivo and in vitro functional assays, the clinical expression analysis discovered that high PYGO2 expression acts as an oncogenic driver of prostate cancer, which overexpression of PYGO2 protein was related to LNM and bone metastasis, high-grade cancer, and biochemical recurrence (BCR) (19). This evidence concerns the gene PYGO2 and Familial prostate cancer.